News
CRMD
4.290
+3.13%
0.130
Needham Maintains Buy on Cormedix, Raises Price Target to $13
Benzinga · 11/11 08:58
CorMedix GAAP EPS of -$0.17 beats by $0.06, revenue of $6.82M
Seekingalpha · 11/10 12:36
Cormedix Q3 EPS $(0.17) Beats $(0.23) Estimate
Benzinga · 11/10 12:31
Earnings Scheduled For November 10, 2022
Benzinga · 11/10 09:23
-- Earnings Flash (CRMD) CORMEDIX Posts Q3 Revenue $6,817
-- Earnings Flash (CRMD) CORMEDIX Posts Q3 Revenue $6,817
MT Newswires · 11/10 07:51
Notable earnings before Thursday's open
Seekingalpha · 11/09 16:29
CorMedix Announces CMS Revision To NTAP Reimbursement Of DefenCath
Benzinga · 11/07 13:33
BRIEF-Cormedix Inc. To Report Q3 Results On Nov 10
Reuters · 11/02 13:09
CorMedix Inc. Announces Abstract Presentation at Upcoming American Society of Nephrology Conference
BERKELEY HEIGHTS, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases,...
GlobeNewswire · 10/20 12:30
CorMedix Inc. to Present at the H.C. Wainwright Annual Global Investment Conference
BERKELEY HEIGHTS, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, tod...
GlobeNewswire · 09/07 12:30
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.
Benzinga · 08/31 18:52
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $4,100 Today
  Cormedix (NASDAQ:CRMD) has outperformed the market over the past 10 years by 2.86% on an annualized basis producing an average annual return of 14.54%. Currently, Cormedix has a market capitalization of $167.76 million.
Benzinga · 08/16 14:03
--Truist Securities Lowers CorMedix's Price Target to $16 From $27, Maintains Buy Rating
--Truist Securities Lowers CorMedix's Price Target to $16 From $27, Maintains Buy Rating
MT Newswires · 08/12 11:01
BRIEF-Cormedix Inc Posts Q2 Loss Per Share $0.19
BRIEF-Cormedix Inc Posts Q2 Loss Per Share $0.19
Reuters · 08/11 13:50
CorMedix GAAP EPS of -$0.19 beats by $0.02, revenue of $0.02M
CorMedix press release (<span class="ticker-hover-wr...
Seekingalpha · 08/11 12:02
Dow Drops Over 100 Points; Verona Pharma Shares Jump
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 100 points on Tuesday.
Benzinga · 08/09 19:11
Nasdaq Tumbles 1.5%; BBQ Holdings Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Nasdaq dropping around 1.5% on Tuesday.
Benzinga · 08/09 17:01
PHAT and SKYX among mid-day movers
Gainers: BBQ Holdings (BBQ) +46%. Verona Pharma (<a href="...
Seekingalpha · 08/09 17:01
Verona, Mersana top healthcare gainers; CorMedix, Quanterix lead losers' pack
Gainers: Verona Pharma (VRNA) +87%. Mersana Therapeutics (<a href="htt...
Seekingalpha · 08/09 14:06
More
Webull provides a variety of real-time CRMD stock news. You can receive the latest news about Cormedix through multiple platforms. This information may help you make smarter investment decisions.
About CRMD
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's primary focus is on the development of its lead product candidate, DefenCath, for commercialization in the United States. The DefenCath/Neutrolin is an anti-infective solution, a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL intended for the reduction of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings such as hemodialysis and total parenteral nutrition. DefenCath product is available in Europe and other territories under the brand name Neutrolin.